Follicular Lymphoma: Triple-Agent Combination Therapy Phase II Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
PrECOG 0403 Phase II Trial Results
- January 5, 2022
On December 11-13, 2021, researchers from University of Virginia led by Craig A. Portell presented PrECOG 0403 Phase II trial results at the 63rd American Society of Hematology Annual Meeting, evaluating venetoclax plus obinutuzumab plus bendamustine as first-line therapy in high-tumor-burden follicular lymphoma.
Trial Design
Patient Population: High-tumor-burden follicular lymphoma (n=56)
Treatment (28-day cycles):
- Venetoclax 800 mg daily (Days 1-10)
- Obinutuzumab 1000 mg daily (Day 1: 100 mg, Day 2: 900 mg, Days 8,15: 1000 mg)
- Bendamustine 90 mg/m² (Days 1-2)
Primary Endpoint: Complete response rate
Patient Demographics
Median age: 62 years (range 33-79)
- Male: 63% (n=35)
- Female: 38% (n=21)
- Stage II: 4%, Stage III: 29%, Stage IV: 68%
Key Efficacy Results
Complete Response Rate: 73.2%
Two-Year Outcomes (median follow-up 20.9 months):
- Overall survival: 94.4%
- Progression-free survival: 85.8%
Safety Profile
Adverse Events (≥20% incidence):
- Nausea: 82.1%
- Fatigue: 60.7%
- Vomiting: 46.4%
- Diarrhea: 42.9%
- Thrombocytopenia: 41.1%
- Neutropenia: 37.5%
- Headache: 28.6%
- Anorexia: 26.8%
- Anemia: 21.4%
Grade 3-4 Toxicities: 83.9%
- Neutropenia: 16.1%
- Tumor lysis syndrome: 14.3%
- Thrombocytopenia: 14.3%
Clinical Conclusions
Venetoclax plus obinutuzumab plus bendamustine achieves high complete response rates in high-tumor-burden follicular lymphoma with improved progression-free survival, though Grade 3-4 toxicity rate (83.9%) requires continued safety monitoring.
Data Source
American Society of Hematology Annual Meeting 2021, Paper 145217
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.